Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | STK10 | O94804 | 1/20 | 0.30 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22058709 | 0.90 | AKT1 (0.32) | AKT1STK10SLK | |
| SCHEMBL15947103 | 0.89 | AKT1 (0.32) | AKT1STK10SLK | |
| SCHEMBL4568628 | 0.89 | AKT1 (0.34) | AKT1STK10SLKMEN1KMT2A | |
| SCHEMBL13868684 | 0.88 | AKT1 (0.35) | AKT1STK10SLKMEN1KMT2A | |
| SCHEMBL13868702 | 0.88 | KDM4E (0.33) | AKT1STK10SLKADAM17MEN1 | |
| SCHEMBL13868715 | 0.88 | AKT1 (0.34) | AKT1STK10SLKMEN1KMT2A | |
| SCHEMBL26032649 | 0.86 | AKT1 (0.34) | AKT1STK10SLKADAM17KMT2A | |
| SCHEMBL15452264 | 0.86 | AKT1 (0.35) | AKT1 | |
| SCHEMBL21636950 | 0.86 | CYP3A4 (0.35) | AKT1STK10SLKKMT2A | |
| SCHEMBL15947090 | 0.85 | STK10 (0.31) | STK10SLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463280-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | AKT1 3152/4885STK10 1610/4885SLK 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.